A Randomized, Double-blind, Placebo Controlled Study, Designed to Investigate the Effect of Ranolazine on Left Ventricular Diastolic Function in Patients With Symptomatic AF and Preserved Ejection Function, After the Subject Has Undergone a Successful External Electrical Cardioversion

Trial Profile

A Randomized, Double-blind, Placebo Controlled Study, Designed to Investigate the Effect of Ranolazine on Left Ventricular Diastolic Function in Patients With Symptomatic AF and Preserved Ejection Function, After the Subject Has Undergone a Successful External Electrical Cardioversion

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2015

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Atrial fibrillation; Heart failure
  • Focus Therapeutic Use
  • Acronyms RAD-HF
  • Most Recent Events

    • 25 Feb 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 03 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top